Thymosin Alpha-1
Compoundable (Rx)Immune Peptides · Immune Modulation
Thymosin Alpha-1 is a 28-amino acid peptide naturally produced by the thymus gland that plays a critical role in immune system regulation.
What is Thymosin Alpha-1?
Thymosin Alpha-1 is a 28-amino acid peptide naturally produced by the thymus gland that plays a critical role in immune system regulation. It is approved in over 35 countries for hepatitis B/C treatment and used as an immune adjuvant. Interest surged post-COVID for its immune-modulating properties.
Also known as: Tα1, Ta1
How Does Thymosin Alpha-1 Work?
Enhances T-cell maturation and function, promotes dendritic cell differentiation, modulates cytokine production (IL-2, IFN-α, IFN-γ), and activates natural killer cells. Restores immune balance rather than simply boosting immunity, making it useful in both immunodeficiency and autoimmune conditions.
What is Thymosin Alpha-1 Used For?
- Immune modulation
- Hepatitis B/C
- Cancer adjuvant therapy
- Vaccine enhancement
- Infection resistance
Potential Side Effects
- Injection site irritation
- Mild flu-like symptoms (rare)
- Rash (very rare)
Contraindications
- Organ transplant recipients
- Immunosuppressive therapy
FDA Legal Status
United States — FDA
Compoundable (Rx)Category 1 (restored 2026)
Related Peptides
KPV
Compoundable (Rx)Anti-Inflammatory Peptides
KPV is a naturally occurring tripeptide (Lys-Pro-Val) derived from the C-terminal end of alpha-melanocyte-stimulating ho...
LL-37
Research OnlyAntimicrobial Peptides
LL-37 is the only human cathelicidin antimicrobial peptide, playing a key role in innate immune defense. It has broad-sp...
Frequently Asked Questions
What is Thymosin Alpha-1 used for?
Is Thymosin Alpha-1 safe for autoimmune conditions?
Quick Facts
- Legal Status (USA)
- Compoundable (Rx)
- FDA Category
- Category 1 (restored 2026)
- Evidence Rating
- AStrong Evidence (Multiple RCTs)
- Class / Subclass
- Immune Peptides / Immune Modulation
- Administration
- subcutaneous
- Typical Dosage
- 1.6mg twice weekly
- Half-Life
- ~2 hours
- Brand Names
- Zadaxin
- Year Discovered
- 1977
- Approval Year
- 1999
Sources
Last updated: 2026-04-01
Sources & references
Primary sources used for the dosing, mechanism, side-effect, and regulatory claims on this page. Verify time-sensitive information (regulatory status, prescribing details) on the source before relying on it for medical decisions. See our disclaimer.
- PubMed PMID 17078754 — peer-reviewed primary literature on Thymosin Alpha-1.
- FDA Federal Register — official notice record for FDA regulatory actions and Category 1 / 503A bulk-substance updates.